NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

Various factors seem to have contributed to 23andMe’s decline. Its kits are a one-time product, so there is little prospect ...

Pharmaceutical companies and precision medicine companies could also use the data to develop new drugs. It wouldn’t be the ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

The collapse of 23andMe is sparking important conversations — and unanswered questions — about genetic data privacy and ...

A New Jersey judge ruled that prosecutors can use evidence from a powerful and increasingly common DNA tool in the upcoming trial of a man charged in the 2018 murder of four relatives. Monmouth ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely targeted infusions. By Gina Kolata Researchers have corrected a disease ...

GSK Pushes First-in-Class Antibiotic for Uncomplicated UTI By March 26, the FDA is scheduled to release its verdict on GSK’s investigational antibiotic gepotidacin for the treatment of uncomplicated ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

Scientists found that rapidly evolving DNA regions, known as human accelerated regions (HARs), help human neurons form complex networks, contributing to higher brain function but possibly increasing ...